scholarly journals Assessing clinical performance in cardiac surgery. Does a specialised clinical database make a difference?

2006 ◽  
Vol 5 (2) ◽  
pp. 123-127 ◽  
Author(s):  
D. Fortuna
Clinical Risk ◽  
2010 ◽  
Vol 16 (4) ◽  
pp. 130-134 ◽  
Author(s):  
Samer AM Nashef

Quality monitoring in medicine was a neglected field until the last two decades. Doctors traditionally did their best, but how good that was could not be evaluated. This situation remains in some areas of medicine, but specialties with clearly-defined interventions and outcomes have progressed in quality of care evaluation, and cardiac surgery leads the way. Measuring the risk of an intervention allows prediction of the outcome and is essential for quality monitoring: without knowing the predicted outcome, the actual outcome cannot be evaluated. Cardiac surgery risk models like EuroSCORE and others have been adopted worldwide, so that measuring risk-adjusted performance is now an integral part of the delivery of good cardiac surgical care. When mortality for a procedure is higher for one surgeon (or hospital) than another, this can be due to one of three reasons, or a combination of the three: the difference is due to chance, or variation in risk profile, or better and safer service. We now have the tools to distinguish between the above factors. We can also observe performance over time: cusum curves plot the performance of surgeons and hospitals by showing hypothetical ‘lives saved’. This provides early warning of deterioration in performance before a problem reaches statistical significance. With the appropriate tools, it is possible not only to identify a problem, but also to anticipate and thus prevent a problem from happening. Monitoring clinical performance is an exciting and rewarding field for future development, and one that will yield real improvements in patient outcomes.


1996 ◽  
Vol 24 (6) ◽  
pp. 705-709 ◽  
Author(s):  
W. J. Russell ◽  
S. Micik ◽  
S. Gourd ◽  
H. Mackay ◽  
S. Wright

Tissue irritation, as evidenced by phlebitis, associated with Optiva™ (Johnson & Johnson Medical) and Insyte™ (Becton Dickinson) polyurethane cannulae was studied. The integrity of the cannulae on removal, the incidence of infection at the cannula site and the factors which influence phlebitis were also examined. One thousand and eight patients had a polyurethane cannula placed for induction of anaesthesia for cardiac surgery. After surgery, the cannula was examined every 24 hours. If evidence of phlebitis occurred, the cannula was removed and sent for culture. All remaining cannulae were removed at 72 hours and the site examined daily for a further three days. There were 503 Optiva™ and 505 Insyte™ cannulae studied. The distributions between the two cannulae with respect to patient characteristics, gauge of cannula, number of attempts and difficulty of insertion, cannula site and anaesthetist inserting were similar. The early removal rate for both groups was 47%. Overall phlebitis rate with Optiva™ was 31% and Insyte™ 33%. This difference is not statistically significant. The cumulative phlebitis rate increased with time but did not differ between the two types of cannulae. Minor tip distortion or shaft kinking of the cannulae occurred in 16.2% of Optiva™ and 23.5% of Insyte™. This difference is statistically significant and may relate to the slightly more acute taper at the Optiva™ cannula tip. Both cannulae were similar in clinical performance.


1997 ◽  
Vol 25 (1) ◽  
pp. 42-47 ◽  
Author(s):  
W. J. Russell ◽  
S. Micik ◽  
S. Gourd ◽  
H. Mackay ◽  
S. Wright

Tissue irritation, as evidenced by phlebitis, associated with Optiva™ (Johnson & Johnson Medical) and Insyte™ (Becton Dickinson) polyurethane cannulae was studied. The integrity of the cannulae on removal, the incidence of infection at the cannula site and the factors which influence phlebitis were also examined. One thousand and eight patients had a polyurethane cannula placed for induction of anaesthesia for cardiac surgery. After surgery, the cannula was examined every 24 hours. If evidence of phlebitis occurred, the cannula was removed and sent for culture. All remaining cannulae were removed at 72 hours and the site examined daily for a further three days. There were 503 Optiva™ and 505 Insyte™ cannulae studied. The distributions between the two cannulae with respect to patient characteristics, gauge of cannula, number of attempts and difficulty of insertion, cannula site and anaesthetist inserting were similar. The early removal rate for both groups was 47%. Overall phlebitis rate with Optiva™ was 31% and Insyte™ 33%. This difference is not statistically significant. The cumulative phlebitis rate increased with time but did not differ between the two types of cannulae. Minor tip distortion or shaft kinking of the cannulae occurred in 16.2% of Optiva™ and 23.5% of Insyte™. This difference is statistically significant and may relate to the slightly more acute taper at the Optiva™ cannula tip. Both cannulae were similar in clinical performance.


2010 ◽  
Vol 24 (6) ◽  
pp. 571-583 ◽  
Author(s):  
Mark Exworthy ◽  
Glenn Smith ◽  
Jonathan Gabe ◽  
Ian Rees Jones

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4467-4467 ◽  
Author(s):  
Fareen Din ◽  
Michael J. Kovacs ◽  
Ron Butler ◽  
Alejandro Lazo-Langner

Abstract Abstract 4467 Background HIT is a potentially serious complication of heparin therapy. Because of the multiple conditions potentially causing thrombocytopenia, particularly in clinical scenarios such as patients undergoing CS or admitted to intensive care units, its diagnosis is frequently not straightforward and depends on a combination of clinical suspicion and laboratory tests. The 4Ts score has been proposed as a tool to assess the pretest probability of a HIT diagnosis (as low, intermediate or high) and it comprises 4 clinical parameters: severity and timing of onset of thrombocytopenia, development of thrombosis, and the presence of alternate causes for thrombocytopenia. This score has several handicaps including the fact that the temporal profile of thrombocytopenia onset is frequently unclear, the history of previous heparin exposure is not always available, the diagnosis of new thrombosis (including extensions of previous ones) is often difficult, and the judgment about the likelihood of an alternate cause for the thrombocytopenia is entirely subjective. The clinical usefulness of a scoring system depends mainly on its robustness and reproducibility and therefore inclusion of difficult to evaluate or subjective components might compromise its clinical performance. Objectives We evaluated the inter-observer agreement for classifying the probability of HIT in a population of patients undergoing CS. Methods We conducted a retrospective study of patients admitted for cardiac surgery to our institution between January 2006 and December 2008 and in whom HIT was suspected. Clinical information including all necessary data for calculating the 4 components of the 4Ts score was collected in a standardized database which was used by 2 independent observers (blinded to serological tests results) to calculate the score and the pretest probability for HIT as low (≤3 points), intermediate (4-5 points), or high (≥6 points). Scores assigned by both observers were compared using a Wilcoxon signed ranks test and the inter-observer agreement for scores and pretest probabilities was evaluated using a Kappa statistic. 95% confidence intervals for proportions were estimated using the Wilson score method. Results 73 patients were included in the analysis. The score assigned by both observers differed in 40 cases (54.8%; 95% CI 43.4, 65.7; p=0.001). The value of the Kappa statistic for the inter-observer agreement for scores was 0.266 (95% CI 0.111, 0.421) and for pretest probabilities was 0.400 (95% CI 0.218, 0.582). Conclusions In this study, we found that the 4Ts score has an inter-observer agreement ranging between slight and moderate when applied to patients undergoing CS. The variability observed in the assessment of the score raises doubts about its usefulness when evaluating the possibility of HIT in this patient population. Limitations of this study include a relatively small sample size, inclusion of a single clinical setting, and its retrospective nature. Further studies in this and other populations are needed to assess the reproducibility of the 4Ts score. Disclosures: No relevant conflicts of interest to declare.


JAMA ◽  
1966 ◽  
Vol 195 (5) ◽  
pp. 356-361 ◽  
Author(s):  
J. B. McClenahan
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document